On Tuesday Aethlon Medical, Inc. (NASDAQ: AEMD) has shown downward move of -0.94% and ended the last trade at $1.05. The trading volume was recorded to 51,513 shares as compared to average traded volume of 80,676 shares.
Aethlon Medical, Inc. (NASDAQ: AEMD) reported results for its fiscal year ended March 31, 2018.
At March 31, 2018, the Company had a cash balance of about $7.0M.
Consolidated operating costs and expenses were about $5.0M for the fiscal year ended March 31, 2018 contrast to $6.5M in the fiscal year ended March 31, 2017, a decrease of $1.5M. The $1.5M decrease was Because of reductions in payroll and related expenses of about $844,000, in professional fees of about $608,000 and in general and administrative expense of about $57,000.
The $844,000 decrease in payroll and related expenses was principally driven by a $926,000 decrease in our stock-based compensation, which was partially offset by an $81,000 increase in cash payroll and related expenses Because of headcount additions in our scientific staff.
The $608,000 decrease in our professional fees was Because of reductions in our non-DARPA-related professional fees of $546,000, in our DARPA-related professional fees of $39,000 and in Exosome’s professional fees of $24,000. The primary factors in the $546,000 decrease in our non-DARPA-related professional fees were a $224,000 reduction in legal fees Because of a reduction in registration statement and financing activity in FY’18 contrast to FY’17, a $146,000 reduction in clinical trial expense Because of the conclusion of our clinical trial and a $114,000 reduction in business development expense. The primary factor in our $39,000 decrease in our DARPA-related professional fees was the completion of our DARPA contract in September 2016.
The $57,000 decrease in general and administrative expenses primarily arose from reductions in the general and administrative expenses in our DARPA-related activities of $102,000 and in the general and administrative expenses at Exosome of $30,000, which were partially offset by increases in our non-DARPA-related activities of $75,000.
The Company had other expense of about $869,000 for fiscal 2018 in the third quarter of fiscal 2018 contrast to other expense of about $1.2M in for fiscal 2017.
During fiscal 2018, the Company recorded $149,625 in revenues under its contract with the National Cancer Institute. During fiscal 2017, the recorded $392,073 in revenue from its government contract with DARPA.
Aethlon Medical, Inc.’s (AEMD) stock price showed weak performance of -3.67% in last seven days, switched down -14.63% in last thirty days and it fell -27.59% in last one year.
It has 17.85 million of outstanding shares and its shares float measured at 16.75.
The net loss was about $5.7M, or $(0.468) per share for fiscal 2018 contrast to a net loss of about $7.3M, or $(0.94) for fiscal 2017.